Imbria Pharmaceuticals
Latest round
- Series B
Last raised
- Mar 2025
Total raised
- $59M
Investors
- 6
About Imbria Pharmaceuticals
Imbria Pharmaceuticals is focused on developing innovative therapies for cardiometabolic disorders, particularly targeting conditions like non-obstructive hypertrophic cardiomyopathy and heart failure. The company aims to enhance treatment outcomes for patients through advanced drug development. Imbria Pharmaceuticals, Inc. is dedicated to the development of novel treatments for cardiometabolic disorders. Founded in 2018 in Boston, US, the company has engaged in one significant deal to date. In March 2025, Imbria Pharmaceuticals, Inc. As of May 2025, Alvin Shih is the Chief Executive Officer (CEO) of the company. Imbria Pharmaceuticals specializes in developing novel therapies aimed at treating cardiometabolic disorders, specifically focusing on conditions such as non-obstructive hypertrophic cardiomyopathy (HCM), stable angina, and heart failure with preserved ejection fraction (HFpEF). Their core product, Ninerafaxstat, is designed to optimize cellular energy metabolism in the heart, addressing the underlying pathophysiology of these conditions. By leveraging their understanding of cellular metabolism, Imbria seeks to provide new treatment options for patients who face limited or inadequate therapies. The primary target demographic includes patients suffering from HCM, stable angina, and HFpEF, which collectively impact a significant portion of the adult population globally. Imbria's products are aimed at markets primarily in North America and Europe, where there is a recognized need for advanced treatment modalities in cardiometabolic health. Imbria Pharmaceuticals generates revenue through strategic partnerships and collaborations in the pharmaceutical landscape, particularly through clinical trials and product development agreements for their lead candidate, Ninerafaxstat. The business model may involve licensing agreements with larger pharmaceutical firms, who may seek to co-develop or commercialize these innovative therapies. Transactions typically occur through structured agreements that outline milestones, including upfront payments and potential royalties based on the successful commercialization of their products.
Who invested in Imbria Pharmaceuticals
6 investors across 1 round
See all investors in Imbria Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Mar 10, 2025
Amount
$59M
Investors
Questions about Imbria Pharmaceuticals
Who invested in Imbria Pharmaceuticals?
Imbria Pharmaceuticals has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Imbria Pharmaceuticals raised?
Imbria Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Imbria Pharmaceuticals last raise money?
Imbria Pharmaceuticals's most recent round on record is a Series B, in Mar 2025.
What does Imbria Pharmaceuticals do?
Imbria Pharmaceuticals is focused on developing innovative therapies for cardiometabolic disorders, particularly targeting conditions like non-obstructive hypertrophic cardiomyopathy and heart failure.
Where is Imbria Pharmaceuticals headquartered?
Imbria Pharmaceuticals is headquartered in Boston, US.
Which VCs invest in companies like Imbria Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back healthcare it companies at Imbria Pharmaceuticals's stage. Their profiles are linked below.
VCs backing healthcare it startups at Series B
Raising like Imbria Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.